Trial of CF101 to Treat Patients With Psoriasis

Summary

Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.

Timeline

Start

2011-07

Primary completion

2015-03

Completion

2015-05

Outcome

Missed primary endpoint

release “announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.” canfite.com ↗

release “While the Phase II/III study did not meet its primary efficacy endpoint at week 12” canfite.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Piclidenoson	Small molecule	2 mg	Oral

Indications